Prostate drug boosts PFS in metastatic disease
'This is very different from chemotherapy,' study author says
5th June 2019
In men with metastatic castration-sensitive prostate cancer, adding apalutamide to conventional androgen-deprivation therapy can produce a 52% increase in the rate of radiographic progression-free survival, researchers report.